Biodesix Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Biodesix Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 8071 — Services-Medical Laboratories
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Louisville
- Headquarters state / province
- Colorado
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- BDSX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001439725
- EIN
- 20-3986492
Board of directors
-
Charles M. Watts · DirectorSince 2023
-
Hany Massarany · DirectorSince 2023
-
Jack W. Schuler · DirectorSince 2023
-
Jean M. Franchi · DirectorSince 2023
-
John Patience · DirectorSince 2023
-
Jon Faiz Kayyem · DirectorSince 2023
-
Lawrence T. Kennedy Jr. · DirectorSince 2023
-
Matthew Strobeck · DirectorSince 2023
-
Scott Hutton · Director · President & CEOSince 2023
Chief executives
Scott Hutton
· President & CEO
Dates unknown
Director election results
Annual meeting of May 19, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
100.0%
-
100.0%
Board connections
2 of this board's directors also sit on 2 other boards.
- via Jon Faiz Kayyem
- via Matthew Strobeck
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $3,117,548
- 6 purchases by 1 insider
- Sold, last 12 months
- $118,381
- 20 sales by 5 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 12, 2026 | Jack W. Schuler 10% owner, Emeritus Director | Open-market purchase | +15,000 | $24.47 | $366,992 |
| Aug 11, 2026 | Jack W. Schuler 10% owner, Emeritus Director | Open-market purchase | +13,700 | $24.01 | $328,911 |
| Aug 10, 2026 | Jack W. Schuler 10% owner, Emeritus Director | Open-market purchase | +13,900 | $24.25 | $337,029 |
| Jun 30, 2026 | John Patience Director, Chairman | Option exercise | +1,361 | — | — |
| Mar 31, 2026 | John Patience Director, Chairman | Option exercise | +1,361 | — | — |
| Feb 23, 2026 | Vazquez Chris Officer (Chief Accounting Officer) | Open-market sale | −211 | $12.78 | $2,697 |
| Feb 23, 2026 | Scott Hutton Director, Officer (President & CEO) | Open-market sale | −1,490 | $12.78 | $19,042 |
| Feb 23, 2026 | Pestano Gary Anthony Officer (Chief Development Officer) | Open-market sale | −556 | $12.78 | $7,106 |
| Feb 23, 2026 | O'Kane Kieran Officer (Chief Commercial Officer) | Open-market sale | −535 | $12.78 | $6,837 |
| Feb 23, 2026 | Cowie Robin Harper Officer (CFO, Sec'y & Treasurer) | Open-market sale | −535 | $12.78 | $6,837 |
| Feb 20, 2026 | Vazquez Chris Officer (Chief Accounting Officer) | Option exercise | +563 | — | — |
| Feb 20, 2026 | Scott Hutton Director, Officer (President & CEO) | Option exercise | +4,844 | — | — |
| Feb 20, 2026 | Pestano Gary Anthony Officer (Chief Development Officer) | Option exercise | +1,528 | — | — |
| Feb 20, 2026 | O'Kane Kieran Officer (Chief Commercial Officer) | Option exercise | +1,469 | — | — |
| Feb 20, 2026 | Cowie Robin Harper Officer (CFO, Sec'y & Treasurer) | Option exercise | +1,469 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.